NCT06649227View on ClinicalTrials.gov

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2029

Conditions
Relapsed Adult AML
Interventions
DRUG

CAR-T cell therapy

cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

University Hospital, Rouen

OTHER

collaborator

Miltenyi

UNKNOWN

lead

University Hospital, Lille

OTHER